These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38108548)

  • 1. Development and application of neonatal physiology-based pharmacokinetic models of amikacin and fosfomycin to assess pharmacodynamic target attainment.
    Darlow CA; Parrott N; Peck RW; Hope W
    CPT Pharmacometrics Syst Pharmacol; 2024 Mar; 13(3):464-475. PubMed ID: 38108548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of antibiotic resistance, drug target attainment, bacterial pathogenicity and virulence, and antibiotic access and affordability on outcomes in neonatal sepsis: an international microbiology and drug evaluation prospective substudy (BARNARDS).
    Thomson KM; Dyer C; Liu F; Sands K; Portal E; Carvalho MJ; Barrell M; Boostrom I; Dunachie S; Farzana R; Ferreira A; Frayne F; Hassan B; Jones E; Jones L; Mathias J; Milton R; Rees J; Chan GJ; Bekele D; Mahlet A; Basu S; Nandy RK; Saha B; Iregbu K; Modibbo F; Uwaezuoke S; Zahra R; Shirazi H; Syed NU; Mazarati JB; Rucogoza A; Gaju L; Mehtar S; Bulabula ANH; Whitelaw A; van Hasselt JGC; Walsh TR;
    Lancet Infect Dis; 2021 Dec; 21(12):1677-1688. PubMed ID: 34384533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance.
    Darlow CA; Docobo-Perez F; Farrington N; Johnson A; McEntee L; Unsworth J; Jimenez-Valverde A; Gastine S; Kolamunnage-Dona R; de Costa RMA; Ellis S; Franceschi F; Standing JF; Sharland M; Neely M; Piddock L; Das S; Hope W
    Antimicrob Agents Chemother; 2021 Jun; 65(7):e0029321. PubMed ID: 33972238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy.
    Sime FB; Johnson A; Whalley S; Santoyo-Castelazo A; Montgomery AB; Walters KA; Lipman J; Hope WW; Roberts JA
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27795380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised controlled trial of fosfomycin in neonatal sepsis: pharmacokinetics and safety in relation to sodium overload.
    Obiero CW; Williams P; Murunga S; Thitiri J; Omollo R; Walker AS; Egondi T; Nyaoke B; Correia E; Kane Z; Gastine S; Kipper K; Standing JF; Ellis S; Sharland M; Berkley JA;
    Arch Dis Child; 2022 Sep; 107(9):802-810. PubMed ID: 35078765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Potential Role of Fosfomycin in Neonatal Sepsis Caused by Multidrug-Resistant Bacteria.
    Li G; Standing JF; Bielicki J; Hope W; van den Anker J; Heath PT; Sharland M
    Drugs; 2017 Jun; 77(9):941-950. PubMed ID: 28456943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IV and oral fosfomycin pharmacokinetics in neonates with suspected clinical sepsis.
    Kane Z; Gastine S; Obiero C; Williams P; Murunga S; Thitiri J; Ellis S; Correia E; Nyaoke B; Kipper K; van den Anker J; Sharland M; Berkley JA; Standing JF
    J Antimicrob Chemother; 2021 Jun; 76(7):1855-1864. PubMed ID: 33855449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance.
    Darlow CA; Farrington N; Johnson A; McEntee L; Unsworth J; Jimenez-Valverde A; Kolamunnage-Dona R; Da Costa RMA; Ellis S; Franceschi F; Sharland M; Neely M; Piddock LJV; Das S; Hope W
    J Antimicrob Chemother; 2022 Apr; 77(5):1334-1343. PubMed ID: 35170719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coli.
    Merino-Bohórquez V; Docobo-Pérez F; Sojo J; Morales I; Lupión C; Martín D; Cameán M; Hope W; Pascual Á; Rodríguez-Baño J
    Clin Microbiol Infect; 2018 Nov; 24(11):1177-1183. PubMed ID: 29649596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential of fosfomycin for multi-drug resistant sepsis: an analysis of in vitro activity against invasive paediatric Gram-negative bacteria.
    Williams PCM; Waichungo J; Gordon NC; Sharland M; Murunga S; Kamau A; Berkley JA
    J Med Microbiol; 2019 May; 68(5):711-719. PubMed ID: 30994430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem plus fosfomycin in paediatrics.
    Martins FS; Zhu P; Heinrichs MT; Sy SKB
    Br J Clin Pharmacol; 2021 Mar; 87(3):1012-1023. PubMed ID: 32638408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher versus standard amikacin single dose in emergency department patients with severe sepsis and septic shock: a randomised controlled trial.
    De Winter S; Wauters J; Meersseman W; Verhaegen J; Van Wijngaerden E; Peetermans W; Annaert P; Verelst S; Spriet I
    Int J Antimicrob Agents; 2018 Apr; 51(4):562-570. PubMed ID: 29180278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis.
    Sherwin CM; Svahn S; Van der Linden A; Broadbent RS; Medlicott NJ; Reith DM
    Eur J Clin Pharmacol; 2009 Jul; 65(7):705-13. PubMed ID: 19305985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetic Study of the Suitability of Standard Dosing Regimens of Amikacin in Critically Ill Patients with Open-Abdomen and Negative-Pressure Wound Therapy.
    Carrié C; Delzor F; Roure S; Dubuisson V; Petit L; Molimard M; Breilh D; Biais M
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria.
    Darlow CA; da Costa RMA; Ellis S; Franceschi F; Sharland M; Piddock L; Das S; Hope W
    Paediatr Drugs; 2021 Sep; 23(5):465-484. PubMed ID: 34435316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales.
    Darlow CA; Hope W
    J Antimicrob Chemother; 2022 Feb; 77(3):711-718. PubMed ID: 34969066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of Penicillin G in Preterm and Term Neonates.
    Padari H; Metsvaht T; Germovsek E; Barker CI; Kipper K; Herodes K; Standing JF; Oselin K; Tasa T; Soeorg H; Lutsar I
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of Optimal Amikacin Dosing Regimens for Pediatric Patients With Burn Wound Sepsis.
    Yu T; Stockmann C; Healy DP; Olson J; Wead S; Neely AN; Kagan RJ; Spigarelli MG; Sherwin CM
    J Burn Care Res; 2015; 36(4):e244-52. PubMed ID: 25185930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of flomoxef combined with amikacin in a hollow-fibre infection model for the treatment of neonatal sepsis in low- and middle-income healthcare settings.
    Darlow CA; McEntee L; Johnson A; Farrington N; Unsworth J; Jimenez-Valverde A; Jagota B; Kolamunnage-Dona R; Da Costa RMA; Ellis S; Franceschi F; Sharland M; Neely M; Piddock L; Das S; Hope W
    J Antimicrob Chemother; 2022 Nov; 77(12):3349-3357. PubMed ID: 36177766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetic/pharmacodynamic target attainment analysis of IV fosfomycin for the treatment of MDR Gram-negative bacterial infections.
    Wangchinda W; Pogue JM; Thamlikitkul V; Leelawattanachai P; Koomanachai P; Pai MP
    J Antimicrob Chemother; 2024 Jun; 79(6):1372-1379. PubMed ID: 38597137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.